list of all glp-1 agonists America's Poison Centers Indications for GLP-1/GIP RA Summary

FOR DIZZINESS SOURCE: DailyMed

Data from the Centers for Disease Control and Prevention (CDC) in 2023 indicated that more than 37 million adults in the United States were living with diabetes, while obesity rates remained considerably high across the region

Drug design, development and therapy

There are concerns that GLP-1 receptor agonists may perform differently in real-world settings, compared to clinical trials

Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population

The proliferation of virtual pharmacies that exist largely to prescribe GLP-1s, with no other long-term patient-doctor relationship, adds to the risk that people go on these drugs without appropriate supervision and support